Almost seven months ahead of the scheduled PDUFA date, Rasonque received FDA approval at the end of August.

For the treatment of pancreatic cancer, this is a milestone that has been waiting for more than 40 years. From the perspective of Revolution Medicines, this twelve year old biotech has finally launched its first product on the market.

Just eight months ago, this company was a "potential stock" with no products and only data, and global pharmaceutical giant Merck was in talks to acquire it for a valuation of up to $30 billion. For the vast majority of biotech companies, being acquired by large pharmaceutical companies at a premium and retiring after achieving success is almost the most perfect outcome that founders can imagine.

But as the CEO of Revolution Medicines, Mark Goldsmith said 'no'.

The negotiations officially broke down in January 2026. The outside world was surprised. Why should a company that has never sold medicine refuse $30 billion?
Eight months later, the answer was revealed.

Rasonque's annual sales forecast quickly rose from billions of dollars on the day of approval to over 9 billion dollars by analysts. Evercore ISI also pushed the long-term sales of pancreatic cancer indications to 15.1 billion dollars. The Biotech also holds a huge pipeline across multiple solid tumors, such as pancreatic cancer, non-small cell lung cancer, colorectal cancer, etc.

Refusing to be bought and then becoming a giant on their own - this story seems to have just begun.

01. The temptation of 30 billion

The immediate reasons for mergers and acquisitions can be traced back to the end of 2025.

At that time, the Phase III clinical data of Revolution Medicines had not yet been fully read out, and there was no product on the market. The research and development expenses burned on the books far exceeded the revenue. But in the understanding of the scientific and industrial communities, the value of this company can no longer be measured by traditional biotech valuation logic.

Revolution Medicines has tackled one of the most challenging targets in the field of cancer - RAS mutations.

RAS gene mutations drive about one-third of human cancers and over 90% of pancreatic tumors. Since scientists discovered the association between RAS mutations and cancer in the early 1980s, countless pharmaceutical companies have been trying to develop targeted drugs for over forty years, but have all failed.

The problem is that due to the smooth surface of RAS protein, there are no grooves that traditional drugs can "get stuck" in, and scientists once labeled it as "non pharmaceutical".

What Revolution Medicines did was tear off this label.

By the end of 2025, while the company's Phase III clinical data was still being compiled, Wall Street and pharmaceutical giants with keen senses had already taken action. In early January 2026, the Financial Times first reported that Merck was in talks to acquire Revolution Medicines, with a possible transaction price ranging from $28 billion to $32 billion.

The news caught the attention of the entire biopharmaceutical industry. $30 billion, which is almost one of the highest prices in biotech mergers and acquisitions in the past few years. For a company that has not yet made a profit, this is beyond the imagination of many people.

However, the negotiations did not last long.

On January 25, 2026, The Wall Street Journal exclusively reported that Merck had terminated its acquisition negotiations due to a failed price negotiation.
According to insiders, there is an insurmountable price gap between Merck's offer and the psychological expectations of Revolution management. This biotech has a higher assessment of its own value than $30 billion.

Some voices question why a company without a product should charge such a high price?

Goldsmith later recalled an earlier moment in an interview with The Wall Street Journal. He said that in 2025, financial institutions will proactively approach and propose to help Revolution Medicines expand its global market. When asked how much financial support is needed, 'I told them they need a lot'. When he thought the other party would stop, he didn't expect them to reply, "We're interested

This conversation has somewhat increased Revolution Medicines' confidence in asking Merck for a price.

The decision to reject MNC seemed somewhat arrogant at the time. There are many successful cases in history for a biotech company to independently complete the entire chain from research and development to commercialization, but they are indeed a minority. The fate of the vast majority of biotech companies is either to be acquired by large companies in the clinical stage or to hand over sales rights to giants after approval.

Revolution Medicines has chosen the third path.

02. "Everyone stand up"

In May 2026, the annual meeting of the American Society of Clinical Oncology, the world's largest oncology conference, was held as scheduled.

At the plenary session, when the Phase III RASolute 302 trial data of Revolution Medicines was fully released for the first time, it won a standing ovation of nearly a minute.
The reason why the audience is so excited is that among patients with metastatic pancreatic ductal adenocarcinoma treated with Rasonque, the median overall survival time reaches 13.2 months. And for patients receiving standard chemotherapy, this number is only 6.7 months. The survival period has almost doubled.

For pancreatic cancer, which is known as the "king of cancer" and has a five-year survival rate of only about 13%, only those who have experienced it can understand what such data means.

In a report by The Wall Street Journal, Neil Williford， An elderly man from Texas was diagnosed with stage IV pancreatic cancer in April 2024, and the cancer cells have spread to the lungs. The doctor told him that he is expected to live for less than a year. Traditional chemotherapy is ineffective for him. In July 2025, he entered the clinical trial of Revolution Medicines and began taking Rasonque.

By the time of approval in August 2026, Williford had already lived for over two years.

Another patient, Jay Williams, 58 years old, was a former executive at Disney. After multiple rounds of chemotherapy, radiation therapy, and a major surgery that failed to stop the cancer from spreading, he began taking Rasonque in July 2025.

This year, Williams and his wife have returned to Disneyland multiple times, walking a mile every day. "What Rasonque can do is buy time for you - and what pancreatic cancer patients lack most is time. ”

The FDA officially approved Rasonque (commonly known as daraxonrasib) for marketing on August 26th, with indications for adult patients with metastatic pancreatic ductal adenocarcinoma who have received at least first-line treatment or are not suitable for multi drug system therapy.

This is the world's first approved broad-spectrum RAS targeted drug.

In terms of pricing, Revolution Medicines has offered a one month price tag of $39800. According to this calculation, the annual treatment cost exceeds 477000 US dollars. The price is not low, but Wall Street believes that Rasonque is worth it.

According to the estimate of Evaluate, if Rasonque can be proved safe and effective in earlier pancreatic cancer and other cancers, the annual sales are expected to exceed 20 billion dollars.

Truist Securities released a report on the day the drug was approved, predicting that Rasonque's sales in 2028 could reach $2.3 billion.

In Evercore ISI's view, Rasonque's 2026 sales forecast can be directly raised to $2.4 billion. In 2034, the sales of Rasonque for pancreatic cancer indications alone will probably reach 15.1 billion dollars.

Leerink Partners is relatively cautious. They pointed out in the report that the side effects of Rasonque, including systemic rash and gastrointestinal problems, left room for differentiated competition among newcomers.

However, regardless, Rasonque can be considered as opening up a brand new track.

03. Building a factory from scratch

On the day of approval, Rasonque was immediately launched. For a company that has never been commercialized before, this is undoubtedly a race against time.

Most biotechnologies choose to collaborate with large pharmaceutical companies before and after drug approval, outsourcing sales and focusing solely on research and development. But Revolution Medicines decided from the beginning to do it all themselves.

Goldsmith revealed in an interview on the day of approval that the company has built its sales team, distribution network, and reimbursement operation system from scratch in the past few months. At the same time, they have also signed overseas production agreements and plan to invest in multiple production lines to prevent supply bottlenecks.
So, where does the money come from?

In April 2026, Revolution Medicines and Royalty Pharma reached a financing agreement of up to $2 billion. Royalty Pharma provided upfront funding and senior secured loans in exchange for partial ownership of Rasonque and another investigational drug for future sales.

By May 2026, Royalty Pharma has paid a second $250 million royalty fee to Revolution Medicines. According to the agreement, if specific milestones are achieved, a maximum of $1.5 billion in committed funds will be available.

Meanwhile, Revolution Medicines has completed a $2.2 billion public fundraising in the capital market. As of June 30, 2026, the company's cash and investments totaled $3.9 billion.

With money, the next step is to form a team.

According to the company's disclosure, Revolution Medicines had already established a complete commercial infrastructure upon approval, including supply chain, distribution network, sales team, patient service, and reimbursement support - all of which were in place on the first day of listing. The company also launched a patient support program called (ON) Path, which covers insurance coordination, financial assistance, and treatment education, helping patients complete the entire process from obtaining a prescription to continuing medication.

During the earnings call, Goldsmith stated that the company's commercialization preparations actually began four months before approval.

On May 1, 2026, the FDA approved an expanded accessible treatment protocol that allows Revolution Medicines to provide medication to some patients prior to formal approval. By the time of formal approval, over 2000 patients had received treatment through the project.

This "paving the way ahead" strategy allowed Rasonque to have a certain market foundation and doctor awareness on the day of approval, greatly shortening the traditional market introduction period.

Truist Securities pointed out that Revolution Medicines achieved drug accessibility on the day of approval, fully demonstrating its level of commercial readiness.

From a purely research-oriented biotech to a pharmaceutical company with complete commercialization capabilities, Revolution Medicines has completed this transformation in less than a year.

04. The Next Generation Cancer Giant

The approval of Rasonque is just the beginning.

In a report in May 2026, Truist Securities described Revolution Medicines as the "next generation cancer giant". This judgment is based not only on Rasonque's data on second-line pancreatic cancer, but also on the company's strategic layout of the whole RAS track.

The first is the deep advancement of pancreatic cancer.

Rasonque is currently approved as a second-line treatment, but Revolution Medicines is already advancing more frontline clinical research.

The Phase III RASolute 303 trial is evaluating Rasonque monotherapy or combination chemotherapy for patients with previously untreated metastatic pancreatic ductal adenocarcinoma. This trial will start patient enrollment in March 2026, and data is expected to be read out in mid-2028.

Bernstein recently estimated that the probability of RASolute 303 trial failure is about 25% - which means the probability of success is as high as 75%. If Rasonque can replicate the second-line survival benefits in first-line pancreatic cancer, its market space will jump from billions of dollars in second-line to tens of billions of dollars.

At the same time, another phase III RASolute 304 trial is evaluating the application of Rasonque in adjuvant treatment of pancreatic cancer. From late stage to early stage, Revolution Medicine is trying to cover every stage of pancreatic cancer treatment.

Next is the horizontal expansion of indications.

The RAS mutation targeted by Rasonque not only drives pancreatic cancer. RAS mutations are also common in common solid tumors such as non-small cell lung cancer and colorectal cancer.

Revolution Medicines is advancing the Phase III RASolve 301 trial to evaluate the efficacy of Rasonque in second - and third line metastatic non-small cell lung cancer. The main completion date for this experiment is expected to be December 2027. In addition, the company is conducting early research in solid tumors.

Truist predicts that Rasonque is expected to expand to multiple indications such as non-small cell lung cancer and colorectal cancer.

Furthermore, it is the depth of the pipeline.

Rasonque is not the only asset of Revolution Medicines. The company is also advancing multiple investigational drugs, including zoldonrasib and its combination therapy, covering multiple registered clinical trials such as RASolute 305 and 309.

This layout concept of "one target, multiple drugs, multiple indications" has enabled Revolution Medicines to build a deep moat on the RAS track.

As Truist analysts have determined, Revolution Medicines is building a lasting competitive barrier in the RAS field, and this expanding halo effect will support faster trial execution, smoother regulatory communication, and more flexible payer access.

Of course, risks also exist.

The side effects of Rasonque, such as rash and gastrointestinal problems, leave room for differentiation among competitors.

BridgeBio, Immuneering, and other companies are advancing their respective RAS targeted drugs, attempting to surpass them in terms of efficacy or tolerability. After giving up on acquiring Revolution Medicines, Merck has instead acquired another oncology biotech, Terns Pharmaceuticals, demonstrating that the giant has not given up on its layout in this field.

But regardless, Revolution Medicines has reached an unprecedented starting point. It took twelve years to overcome the challenges of forty years in the scientific community; It proves the value of independence with one rejection; It opened a whole new era of treatment with a drug.

Afterwards, Revolution Medicines is no longer just a 'promising biotech'. It is becoming the role it has chosen to be - an independent pharmaceutical giant.

reference material:
FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease
Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent
RevMed could become ‘next oncology titan’ with Rasonque nod
Is Revolution ‘the next oncology titan’?  Truist analysts make the case
Mo Shadong, can't you climb high?; Same freehand brushwork